Literature DB >> 27257132

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.

Melissa Bersanelli1, Roberta Minari2, Paola Bordi2, Letizia Gnetti3, Cecilia Bozzetti2, Anna Squadrilli2, Costanza Anna Maria Lagrasta4, Lorena Bottarelli3, Ganna Osipova2, Enrica Capelletto5, Marco Mor6, Marcello Tiseo2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27257132     DOI： 10.1016/j.jtho.2016.05.019

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  62 in total

Review 1.  Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.

Authors:  Roberta Minari; Paola Bordi; Marcello Tiseo
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 2.  Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer.

Authors:  Joan Rou-En Choo; Chee-Seng Tan; Ross A Soo
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

Review 3.  The next tier of EGFR resistance mutations in lung cancer.

Authors:  Hannah L Tumbrink; Alena Heimsoeth; Martin L Sos
Journal:  Oncogene       Date:  2020-10-15       Impact factor: 9.867

4.  Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort.

Authors:  Stephen R Fairclough; Lesli A Kiedrowski; Jessica J Lin; Ori Zelichov; Gabi Tarcic; Thomas E Stinchcombe; Justin I Odegaard; Richard B Lanman; Alice T Shaw; Rebecca J Nagy
Journal:  Exp Hematol Oncol       Date:  2019-10-11

Review 5.  Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.

Authors:  G M O'Kane; T A Barnes; N B Leighl
Journal:  Curr Oncol       Date:  2018-06-13       Impact factor: 3.677

Review 6.  A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.

Authors:  Tao Jiang; Chunxia Su; Shengxiang Ren; Federico Cappuzzo; Gaetano Rocco; Joshua D Palmer; Nico van Zandwijk; Fiona Blackhall; Xiuning Le; Nathan A Pennell; Caicun Zhou
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

7.  Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations.

Authors:  Jaebong Jang; Ciric To; Dries J H De Clercq; Eunyoung Park; Charles M Ponthier; Bo Hee Shin; Mierzhati Mushajiang; Radosław P Nowak; Eric S Fischer; Michael J Eck; Pasi A Jänne; Nathanael S Gray
Journal:  Angew Chem Int Ed Engl       Date:  2020-07-09       Impact factor: 15.336

Review 8.  Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.

Authors:  Shuhang Wang; Yongping Song; Feifei Yan; Delong Liu
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

9.  Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations.

Authors:  Jacqueline H Starrett; Alexis A Guernet; Maria Emanuela Cuomo; Kamrine E Poels; Iris K van Alderwerelt van Rosenburgh; Amy Nagelberg; Dylan Farnsworth; Kristin S Price; Hina Khan; Kumar Dilip Ashtekar; Mmaserame Gaefele; Deborah Ayeni; Tyler F Stewart; Alexandra Kuhlmann; Susan M Kaech; Arun M Unni; Robert Homer; William W Lockwood; Franziska Michor; Sarah B Goldberg; Mark A Lemmon; Paul D Smith; Darren A E Cross; Katerina Politi
Journal:  Cancer Res       Date:  2020-03-19       Impact factor: 12.701

Review 10.  Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.

Authors:  Emma-Anne Karlsen; Sam Kahler; Joan Tefay; Shannon R Joseph; Fiona Simpson
Journal:  Cells       Date:  2021-05-14       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.